

CAMO 2017 ANNUAL SCIENTIFIC MEETING RÉUNION ANNUELLE SCIENTIFIQUE 2017 de l'ACOM



Thursday, April 27, 2017
Jeudi le 27 avril 2017

Chelsea Hotel
Toronto, Ontario

Co-chair: Dr. Rosalyn Juergens
Co-chair: Dr. Krista Noonan



2017

CAMO Annual Scientific Meeting
Réunion annuelle scientifique de l'ACOM
Chelsea Hotel – Toronto, ON

Thursday, April 27 / jeudi le 27 avril 2017 – Room: Mountbatten AB

07h00 – 17h00 CAMO Registration Desk Opens / Ouverture du bureau d'inscription de l'ACOM

07h00 – 08h15 Breakfast Symposium/Déjeuner Conférence

08h15 – 08h30 Coffee Break/Pause-café

08h30 – 10h30 CAMO Oral Presentations/Présentations de résumés

Objectives

At the end of the session, participants will be able to:

1. Describe recent research findings in the field of Medical Oncology.
2. Describe interesting cases in the field of Medical Oncology.

- **CETUXIMAB (CET) CLEARANCE AND SURVIVAL IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) – Dr. Di (Maria) Jiang**
- **INVESTIGATING GENETIC DETERMINANTS OF POOR RESPONSE TO ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH METASTATIC PROSTATE CANCER USING CIRCULATING TUMOUR DNA (CTDNA) – Dr. Daniel Khalaf**
- **THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR Δ /B AGONIST GW501516 SYNERGIZES WITH INFLAMMATORY SIGNALS TO ENHANCE ADOPTIVE CELL THERAPY – Dr. Samuel Saibil**
- **AN EXOME-WIDE ASSOCIATION STUDY OF PANCREATIC CANCER RISK – Dr. Robert Grant**
- **PRIMARY CARE VS. ONCOLOGY-DRIVEN SURVEILLANCE FOLLOWING ADJUVANT CHEMOTHERAPY IN RESECTED PANCREAS CANCER – Dr. Haider Samawi**
- **IMMEDIATE-TERM CHEMOTHERAPY-RELATED COGNITIVE IMPAIRMENT (CRCI) FOLLOWING ADMINISTRATION OF INTRAVENOUS (IV) CHEMOTHERAPY – Dr. Omar F. Khan**
- **PREDICTION OF RELAPSE IN PATIENTS WITH LOCALLY ADVANCED BREAST CANCER AFTER NEOADJUVANT TREATMENT – Dr. Olexiy Aseyev**
- **EGFR AND KRAS MUTATIONS IN ARCHIVAL TISSUE (ATDNA) AND CIRCULATING TUMOR DNA (CTDNA): THE IMPACT OF TUMOR HETEROGENEITY – Dr. Ying Wang**

10h30 – 11h00 Poster viewing and networking break/Présentations d'affiches et réseautage

11h00 – 12h00 CAMO Keynote Speaker

PHYSICIAN ASSISTED DYING: A NEW CANADIAN LANDSCAPE

Speaker: Dr. Jeff Blackmer, Vice-President, Medical Professionalism

Objectives (45 minute presentation, followed by 10 minute Q&A)

At the end of the session, participants will be able to:

1. Explain the legal and legislative background to the assisted dying debate in Canada.
2. Explain the current challenges that remain.
3. Outline the work done by the CMA in representing physicians during this complex process.

12h15 – 13h30 CAMO Annual General Meeting & Lunch/ Réunion d'affaires annuelle de l'ACOM & dîner
([members only/membres seulement](#)) (Room: Wren – 3rd Floor)

12h15 – 13h30 Lunch for Delegates/Dîner des délégués (Room: Mountbatten AB)

2017

CAMO Annual Scientific Meeting
Réunion annuelle scientifique de l'ACOM
Chelsea Hotel – Toronto, ON

Thursday, April 27 / jeudi le 27 avril 2017 – Room: Mountbatten AB

13h45 – 14h00 **CAMO/RX&D Fellowship Presentations**

Best Resident Abstracts

Dr. Bindi Dhesy-Thind – *Chair, Fellowship Committee*

Dr. Rosalyn Juergens & Dr. Krista Noonan – *Co-chairs, Annual Scientific Meeting Committee*

14h00 – 16h55 **CAMO Symposium "A NEW PILLAR OF CANCER TREATMENT: IMMUNOONCOLOGY"**

14h00 – 14h05 **Introduction CAMO Symposium**

Dr. Rosalyn Juergens & Dr. Krista Noonan – *Co-chairs, Annual Scientific Meeting Committee*

14h05 – 14h40 **EVERYTHING YOU ALWAYS WANTED TO KNOW ABOUT IMMUNO-ONCOLOGY (*BUT WERE AFRAID TO ASK)**

Speaker: Dr. Jonathan Bramson, *Professor/McMaster University*

Objectives (25 minute presentation, followed by 10 minute Q&A)

At the end of the session, participants will be able to:

1. Understand the cross-talk between tumor cells and cancer cells that lead to immunosuppression within the tumor.
2. Appreciate the complexity of the cell populations that mediate immunosuppression.
3. Understand the molecular mechanism of leading Immuno-Oncology drugs.

14h40 – 15h15 **CLINICAL LANDSCAPE OF IMMUNOONCOLOGY – WHERE ARE WE NOW AND WHERE ARE WE GOING?**

Speaker: Dr. Michael Smylie, *Medical Oncology Cross Cancer Institute*

Objectives (25 minute presentation, followed by 10 minute Q&A)

At the end of the session, participants will be able to:

1. Explain the mechanism of action of immune checkpoint inhibitors.
2. Discuss the indication to use immune checkpoint inhibitors and in what combination/sequence.
3. List common immune related adverse events and treatment.

15h15 – 15h45 **Poster viewing and networking break/Présentations d'affiches et réseautage**

15h45 – 16h20 **IMPLEMENTING IMMUNOONCOLOGY IN COMMUNITY PRACTICES**

Speaker: Dr. Michael Humphreys, *BC Cancer Agency Medical Oncologist, Vernon, BC*

Objectives (25 minute presentation, followed by 10 minute Q&A)

At the end of the session, participants will be able to:

1. Describe the changing landscape of oncology care and the need to incorporate immuno-oncology (IO) treatments in community oncology practice.
2. Summarize the roles of the multidisciplinary team involved in a successful IO program.
3. List the pillars of IO toxicity management and discuss how to address them in a community oncology setting.

SAVE THE DATE

CAMO 2018 Annual Scientific Meeting
April 26– Toronto, ON

2017

CAMO Annual Scientific Meeting
Réunion annuelle scientifique de l'ACOM
Chelsea Hotel – Toronto, ON

Thursday, April 27 / jeudi le 27 avril 2017 – Room: Mountbatten AB

16h20 – 17h00 **ABSTRACTS – POSTER PRESENTATION LIGHTNING ROUND**

Objectives

At the end of the session, participants will be able to:

1. Describe recent research findings in the field of Medical Oncology.
2. Describe interesting cases in the field of Medical Oncology.

- **EXTERNAL VALIDITY OF CLINICAL TRIALS IN METASTATIC MELANOMA – Mr. Davis Sam**
- **RETROSPECTIVE ANALYSIS OF IPILIMUMAB-INDUCED DIARRHEA AND/OR COLITIS – A SINGLE CENTRE REVIEW – Dr. Marco Iafolla**
- **RATES OF TRASTUZUMAB-ASSOCIATED CARDIOTOXICITY IN HER2-POSITIVE BREAST CANCER PATIENTS AT A TERTIARY CANCER CENTRE – Dr. Roochi Arora**
- **COMPARISON OF DC VS FEC-D ADJUVANT CHEMOTHERAPY IN HORMONE RECEPTOR POSITIVE AND TRIPLE NEGATIVE BREAST CANCER – Dr. Omar F. Khan**
- **ADJUSTMENTS IN RELATIVE DOSE INTENSITY (RDI) FOR ADJUVANT DC OR FEC-D CHEMOTHERAPY IN BREAST CANCER - A POPULATION BASED ANALYSIS – Dr. Zachary Veitch**
- **AGE SHOULD NOT BE A DETERRENT FOR ADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER: A POPULATION-BASED REVIEW – Dr. Shiru Lucy Liu**

Thursday, April 27 / jeudi le 27 avril 2017 – Ontario Heritage Trust

CAMO Awards Dinner* *CAMO members and one guest / Les membres de l'ACOM et un invité*

18h30 – 19h00 **Welcome reception/ Réception de bienvenue**

19h00 – 22h00 **CAMO Awards Dinner**

MOVING WESTWARD – AN OPPORTUNISTIC CAREER IN MEDICAL ONCOLOGY

Speaker: Dr. Vivien Bramwell, MBBS, PhD, FRCP, FRCPC, Medical Oncologist, Tom Baker Cancer Centre/Professor, University of Calgary

Objectives (45 minute presentation, followed by 10 minute Q&A)

At the end of the session, participants will be able to:

1. Contrast a career in medical oncology, started 50 years ago in the UK, with current career paths in Canada.
2. Compare the merits of an opportunistic approach to career development versus prospective strategic career planning.
3. Evaluate leadership possibilities that may occur in a variety of settings.

CAMO Pioneer Lecture Series Award Presentation / CAMO Best Resident Abstract Award Presentation

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.
"This activity was approved by the Canadian Society of Internal Medicine for a maximum of 7 hours".

La présente activité, approuvée par la Société canadienne de médecine interne, est une activité de formation collective agréée au titre de la section 1 conformément au programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada. Maximum de 7 heures.

The Canadian Association of Medical Oncologists
gratefully acknowledges the continued
support of our scientific program
by educational grants from:

DIAMOND LEVEL



GOLD LEVEL



SILVER LEVEL



BRONZE LEVEL

